Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 2/20 | 0.34 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.33 |
| ▸ | PHGDH | O43175 | 3/20 | 0.33 |
| ▸ | MMEL1 | Q495T6 | 1/20 | 0.32 |
| ▸ | MET | P08581 | 1/20 | 0.31 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ALPL | P05186 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | PIN1 | Q13526 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23041497 | 0.92 | MME (0.36) | MMEUSP30PHGDHMMEL1PIN1 | |
| SCHEMBL23041387 | 0.92 | MME (0.36) | MMEUSP30PHGDHMMEL1PIN1 | |
| SCHEMBL23041388 | 0.92 | MME (0.36) | MMEUSP30PHGDHMMEL1PIN1 | |
| SCHEMBL23041498 | 0.92 | MME (0.36) | MMEUSP30PHGDHMMEL1PIN1 | |
| SCHEMBL29707782 | 0.91 | MME (0.37) | MMEUSP30PHGDHMMEL1MET | |
| SCHEMBL23041607 | 0.91 | MME (0.37) | MMEUSP30PHGDHMMEL1MET | |
| SCHEMBL23051965 | 0.90 | CNR2 (0.34) | MMEUSP30PHGDHMMP13 | |
| SCHEMBL28721016 | 0.90 | CNR2 (0.34) | MMEUSP30PHGDHMMP13 | |
| SCHEMBL23041442 | 0.90 | PHGDH (0.35) | MMEUSP30PHGDHMMEL1MET | |
| SCHEMBL23041445 | 0.90 | PHGDH (0.35) | MMEUSP30PHGDHMMEL1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021038426-A1 | SUBSTITUTED 1,3-PHENYL HETEROARYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-03-04 | — | — | WO | disclosed |